199 related articles for article (PubMed ID: 19246908)
1. Cardiovascular disease risk factors and progression of Alzheimer's disease.
Abellan van Kan G; Rolland Y; Nourhashémi F; Coley N; Andrieu S; Vellas B
Dement Geriatr Cogn Disord; 2009; 27(3):240-6. PubMed ID: 19246908
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
3. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
Sanz C; Andrieu S; Sinclair A; Hanaire H; Vellas B;
Neurology; 2009 Oct; 73(17):1359-66. PubMed ID: 19858457
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study.
Cortes F; Nourhashémi F; Guérin O; Cantet C; Gillette-Guyonnet S; Andrieu S; Ousset PJ; Vellas B;
Alzheimers Dement; 2008 Jan; 4(1):22-9. PubMed ID: 18631947
[TBL] [Abstract][Full Text] [Related]
5. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
6. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
Suh GH; Ju YS; Yeon BK; Shah A
Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of rapid decline in mini mental state examination in clinical practice for prognosis in Alzheimer's disease.
Soto ME; Andrieu S; Cantet C; Reynish E; Ousset PJ; Arbus C; Gillette-Guyonnet S; Nourhashémi F; Vellas B;
Dement Geriatr Cogn Disord; 2008; 26(2):109-16. PubMed ID: 18617740
[TBL] [Abstract][Full Text] [Related]
9. A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort).
Nourhashémi F; Ousset PJ; Gillette-Guyonnet S; Cantet C; Andrieu S; Vellas B;
Int J Geriatr Psychiatry; 2008 May; 23(5):460-5. PubMed ID: 17894422
[TBL] [Abstract][Full Text] [Related]
10. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
11. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
[TBL] [Abstract][Full Text] [Related]
12. Long-term progression of Alzheimer's disease in patients under antidementia drugs.
Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Gardette V; Coley N; Cantet C; Gauthier S; Ousset PJ; Vellas B;
Alzheimers Dement; 2011 Nov; 7(6):579-92. PubMed ID: 22055975
[TBL] [Abstract][Full Text] [Related]
13. Nutritional status assessment during Alzheimer's disease: results after one year (the REAL French Study Group).
Guerin O; Soto ME; Brocker P; Robert PH; Benoit M; Vellas B;
J Nutr Health Aging; 2005; 9(2):81-4. PubMed ID: 15791350
[TBL] [Abstract][Full Text] [Related]
14. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of rate of loss of autonomy in Alzheimer's disease patients. A prospective study of the REAL.FR Cohort.
Lechowski L; De Stampa M; Tortrat D; Teillet L; Benoit M; Robert PH; Vellas B;
J Nutr Health Aging; 2005; 9(2):100-4. PubMed ID: 15791353
[TBL] [Abstract][Full Text] [Related]
16. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
Cortes F; Portet F; Touchon J; Vellas B
J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
[TBL] [Abstract][Full Text] [Related]
17. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease progression in the oldest old compared to younger elderly patient: data from the REAL.FR study.
Nourhashémi F; Gillette-Guyonnet S; Rolland Y; Cantet C; Hein C; Vellas B
Int J Geriatr Psychiatry; 2009 Feb; 24(2):149-55. PubMed ID: 18613005
[TBL] [Abstract][Full Text] [Related]
19. Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors.
Roselli F; Tartaglione B; Federico F; Lepore V; Defazio G; Livrea P
Clin Neurol Neurosurg; 2009 May; 111(4):327-30. PubMed ID: 19036496
[TBL] [Abstract][Full Text] [Related]
20. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
